Lusong Luo

Lusong Luo

Company: Beigene

Job title: Senior Vice President, External Innovation


Exploration of Synergistic Effects: RAF Dimer Inhibitor Lifirafenib (BGB- 283) & MEK Inhibitor Mirdametinib (PD-0325901) 9:30 am

How can inhibiting RAF dependent MEK reactivation suppress the proliferation of KRAS mutated cancer cells? Discuss methodologies of inhibiting tumor growths in KRAS mutant xenograft models Deconstruct the pharmacodynamic analysis of synergistic phospho-ERK blockade to confirm the antitumor activity in the KRAS mutant models Explore the decision to support a vertical inhibition strategyRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.